View On Demand

A Breakthrough Treatment For Dry AMD And Diabetic Eye Disease

About the Event

Please join Dr. Brian Levy, CEO of InflammX, and Andrew Gitkin, managing director and co-head of Health Care Investment Banking at Raymond James as they discuss the company and its new drug, Xiflam, a once-a-day pill that is being developed to treat the nearly 15 million Americans who suffer from dry age-related macular degeneration (AMD) and Diabetic Eye Disease.

Mr. Gitkin has 15-years of experience leading life sciences and biotechnology investment practices at companies that include Piper Jaffray, Moelis & Co, and Tavistock. This gives him a unique perspective with which to view InflammX and the opportunity Xiflam represents in the large and growing sector.

Xiflam is an orally administered small molecule which readily crosses the blood-retina barrier to treat ocular inflammation. Currently, there’s no treatment for Dry AMD and the standard of care for Diabetic Eye Disease requires monthly injections into the eye. Adding insult to injury, the treatment is only 50% effective for those who get the shot. Even with these obvious limitations, consumers spend $11.5B per year on the treatment.

Join our webinar with Dr. Levy and Mr. Gitkin as they discuss how Xiflam is poised to disrupt this $11.5B industry.

Watch On-Demand Recording


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.